Phage Therapy Market
Description
The global phage therapy market is estimated to be valued at USD 1.34 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. The global phage therapy market represents a revolutionary approach to combating bacterial infections through the therapeutic application of bacteriophages, naturally occurring viruses that specifically target and destroy bacterial pathogens. As antibiotic resistance continues to escalate worldwide, phage therapy has emerged as a promising alternative treatment modality, offering precision medicine capabilities that can address multidrug-resistant bacterial infections where conventional antibiotics have failed. This innovative therapeutic approach leverages the natural predator-prey relationship between bacteriophages and bacteria, utilizing these microscopic entities to selectively eliminate harmful bacterial strains while preserving beneficial microbiota.
The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.
Market Dynamics
The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.
Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.
Key Features of the Study
The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.
Market Dynamics
The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.
Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.
Key Features of the Study
- This report provides in-depth analysis of the global phage therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global phage therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Armata Pharmaceuticals Inc, BiomX Inc, Pherecydes Pharma SAS, Intralytix Inc, Locus Biosciences Inc, Nextbiotics Ltd, Proteon Pharmaceuticals SA, iNtRON Biotechnology Co Ltd, Micreos BV, Eligo Bioscience SA, FAGŌTAC Therapeutics (or Fagoterapia), Evolution Biotechnologies Inc, Tol ka AI Therapeutics Inc, PrecisionPhage Oy, and Obulytix Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global phage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phage therapy market
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Monophage therapy
- Phage cocktails
- Engineered/recombinant phages
- Phage derived enzymes (e.g., endolysins)
- Combination products (phage + antibiotic or adjunct)
- Target Pathogen Insights (Revenue, USD Bn, 2020 - 2032)
- Gram negative bacteria
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram‐negative bacteria
- Gram positive bacteria
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram‐positive bacteria
- Mixed/other pathogens
- Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Urinary tract infections (UTIs)
- Skin and wound infections
- Bone and joint/implant associated infections
- Respiratory tract infections (including cystic fibrosis)
- Gastrointestinal infections
- Bloodstream/sepsis infections
- Biofilm related chronic infections
- Other indications
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Topical/dermal
- Injectable/intravenous (IV/IM)
- Inhalation/nebulized
- Local instillation (e.g., bladder, wound cavity)
- Other routes
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and specialty clinics
- Research institutes and academic centers
- Ambulatory care/outpatient clinics
- Others (Veterinary clinics)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGŌTAC Therapeutics (or Fagoterapia)
- Evolution Biotechnologies Inc
- Tol ka AI Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
Table of Contents
151 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Phage Therapy Market, By Product
- Global Phage Therapy Market, By Target Pathogen
- Global Phage Therapy Market, By Disease Indication
- Global Phage Therapy Market, By Route of Administration
- Global Phage Therapy Market, By End User
- Global Phage Therapy Market, By Region
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
- 4. Global Phage Therapy Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Monophage therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage cocktails
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Engineered/recombinant phages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage derived enzymes (e.g., endolysins)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination products (phage + antibiotic or adjunct)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 5. Global Phage Therapy Market, By Target Pathogen, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gram negative bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram‐negative bacteria
- Gram positive bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram‐positive bacteria
- Mixed/other pathogens
- 6. Global Phage Therapy Market, By Disease Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Urinary tract infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Skin and wound infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bone and joint/implant associated infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Respiratory tract infections (including cystic fibrosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastrointestinal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bloodstream/sepsis infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biofilm related chronic infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 7. Global Phage Therapy Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical/dermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable/intravenous (IV/IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation/nebulized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Local instillation (e.g., bladder, wound cavity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 8. Global Phage Therapy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and specialty clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research institutes and academic centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory care/outpatient clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Veterinary clinics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 9. Global Phage Therapy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
- 10. Competitive Landscape
- Armata Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BiomX Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pherecydes Pharma SAS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intralytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Locus Biosciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nextbiotics Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Proteon Pharmaceuticals SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- iNtRON Biotechnology Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Micreos BV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eligo Bioscience SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FAGŌTAC Therapeutics (or Fagoterapia)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evolution Biotechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tol ka AI Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PrecisionPhage Oy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Obulytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 12. References and Research Methodology
- References
- Research Methodology
- About us
- *Browse 32 market data tables and 28 figures on ‘Phage Therapy Market' - Global forecast to 2032
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
